Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
Barr, Paul M, Robak, Tadeusz, Owen, Carolyn, Tedeschi, Alessandra, Bairey, Osnat, Bartlett, Nancy L, Burger, Jan A, Hillmen, Peter, Coutre, Steven, Devereux, Stephen, Grosicki, Sebastian, McCarthy, Helen, Li, Jianyong, Simpson, David, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Styles, Lori, James, Danelle, Kipps, Thomas J, Ghia, Paolo
Published in Haematologica (Roma) (01.09.2018)
Published in Haematologica (Roma) (01.09.2018)
Get full text
Journal Article
Long-read Ribo-STAMP simultaneously measures transcription and translation with isoform resolution
Jagannatha, Pratibha, Tankka, Alexandra T, Lorenz, Daniel A, Yu, Tao, Yee, Brian A, Brannan, Kristopher W, Zhou, Cathy J, Underwood, Jason G, Yeo, Gene W
Published in Genome research (20.11.2024)
Published in Genome research (20.11.2024)
Get full text
Journal Article
Functional Adrenal Collision Tumor in a Patient with Cushing’s Syndrome
Zhou, Cathy, Campbell, Michael J., Fananapazir, Ghaneh
Published in Case reports in endocrinology (14.12.2020)
Published in Case reports in endocrinology (14.12.2020)
Get full text
Journal Article
Survival adjusting for crossover: phase 3 study of ibrutinib vs . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma
Coutre, Steven, Tedeschi, Alessandra, Robak, Tadeusz, Barr, Paul M, Owen, Carolyn, Bairey, Osnat, Burger, Jan, Zhou, Cathy, Styles, Lori, James, Danelle F, Kipps, Thomas J
Published in Haematologica (Roma) (01.06.2018)
Published in Haematologica (Roma) (01.06.2018)
Get full text
Journal Article
Skip and save: utility of pelvic x-rays in the initial evaluation of blunt trauma patients
Soto, Jose Raul, M.D., M.P.H, Zhou, Cathy, M.D, Hu, David, M.D, Arazoza, Antonio C., M.D, Dunn, Ernest, M.D, Sladek, Phillip, M.D
Published in The American journal of surgery (01.12.2015)
Published in The American journal of surgery (01.12.2015)
Get full text
Journal Article
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
Zhou, Cathy, Yuan, Zilong, Ma, Weijie, Qi, Lihong, Mahavongtrakul, Angelique, Li, Ying, Li, Hong, Gong, Jay, Fan, Reggie R, Li, Jin, Molmen, Michael, Clark, Travis A, Pavlick, Dean, Frampton, Garrett M, Forcier, Brady, Moore, Elizabeth H, Shelton, David K, Cooke, Matthew, Ali, Siraj M, Miller, Vincent A, Gregg, Jeffrey P, Stephens, Philip J, Li, Tianhong
Published in Journal of hematology and oncology (06.11.2018)
Published in Journal of hematology and oncology (06.11.2018)
Get full text
Journal Article
P617: FIXED‐DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4‐Y FOLLOW‐UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY
Ghia, Paolo, Allan, John, Siddiqi, Tanya, Wierda, William G., Tam, Constantine, Moreno, Carol, Tedeschi, Alessandra, Szafer‐Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, Jim, Szoke, Anita, Barr, Paul M.
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with 18F-FDG PET/CT muscle metrics
Zhou, Cathy, Foster, Brent, Hagge, Rosalie, Foster, Cameron, Lenchik, Leon, Chaudhari, Abhijit J., Boutin, Robert D.
Published in Annals of nuclear medicine (01.03.2020)
Published in Annals of nuclear medicine (01.03.2020)
Get full text
Journal Article
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Samoilova, Olga, Novak, Jan, Ben-Yehuda, Dina, Strugov, Vladimir, Gill, Devinder, Gribben, John G, Hsu, Emily, Lih, Chih-Jian, Zhou, Cathy, Clow, Fong, James, Danelle F, Styles, Lori, Flinn, Ian W
Published in The lancet oncology (01.01.2019)
Published in The lancet oncology (01.01.2019)
Get full text
Journal Article
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Wierda, William G, Allan, John N, Siddiqi, Tanya, Kipps, Thomas J, Opat, Stephen, Tedeschi, Alessandra, Badoux, Xavier C, Kuss, Bryone J, Jackson, Sharon, Moreno, Carol, Jacobs, Ryan, Pagel, John M, Flinn, Ian, Pak, Yvonne, Zhou, Cathy, Szafer-Glusman, Edith, Ninomoto, Joi, Dean, James P, James, Danelle F, Ghia, Paolo, Tam, Constantine S
Published in Journal of clinical oncology (01.12.2021)
Published in Journal of clinical oncology (01.12.2021)
Get full text
Journal Article
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Tam, Constantine S., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Jacobs, Ryan, Opat, Stephen, Barr, Paul M., Tedeschi, Alessandra, Trentin, Livio, Bannerji, Rajat, Jackson, Sharon, Kuss, Bryone J., Moreno, Carol, Szafer-Glusman, Edith, Russell, Kristin, Zhou, Cathy, Ninomoto, Joi, Dean, James P., Wierda, William G., Ghia, Paolo
Published in Blood (02.06.2022)
Published in Blood (02.06.2022)
Get full text
Journal Article
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan
Published in Blood (16.04.2015)
Published in Blood (16.04.2015)
Get full text
Journal Article
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Barr, Paul M., Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A., Hillmen, Peter, Coutre, Steve E., Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian-Yong, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J., Ghia, Paolo
Published in Blood advances (14.06.2022)
Published in Blood advances (14.06.2022)
Get full text
Journal Article
Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study
Ghia, Paolo, Wierda, William G., Barr, Paul M., Kipps, Thomas J., Siddiqi, Tanya, Allan, John N., Hunter, Zoë, Zhou, Cathy, Szoke, Anita, Dean, James P., Tam, Constantine S.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study
Barr, Paul M., Allan, John N., Siddiqi, Tanya, Wierda, William G., Tam, Constantine Si Lun, Moreno, Carolina D., Tedeschi, Alessandra, Szafer-Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, James P., Szoke, Anita, Ghia, Paolo
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Allan, John N, Flinn, Ian W, Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S, Kipps, Thomas J, Barr, Paul M, Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C, Jacobs, Ryan, Kuss, Bryone J, Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G
Published in Clinical cancer research (14.07.2023)
Published in Clinical cancer research (14.07.2023)
Get full text
Journal Article
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
Wierda, William G., Jacobs, Ryan, Barr, Paul M., Allan, John N., Siddiqi, Tanya, Tedeschi, Alessandra, Kipps, Thomas J., O'Brien, Susan Mary, Badoux, Xavier C., Visentin, Andrea, Lasica, Masa, Carney, Dennis, Elinder Camburn, Anna, De La Serna Torroba, Javier, Szafer-Glusman, Edith, Zhou, Cathy, Szoke, Anita, Dean, James P., Ghia, Paolo, Tam, Constantine S.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre
Zhou, Cathy, Urbauer, Diana L., Fellman, Bryan M., Tamboli, Pheroze, Zhang, Miao, Matin, Surena F., Wood, Christopher G., Karam, Jose A.
Published in BJU international (01.05.2016)
Published in BJU international (01.05.2016)
Get full text
Journal Article
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Coutré, Steven E, Furman, Richard R, Flinn, Ian W, Burger, Jan A, Blum, Kristie, Sharman, Jeff, Jones, Jeffrey, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Tran, Anh, Zhou, Cathy, Bilotti, Elizabeth, James, Danelle F, Byrd, John C, O'Brien, Susan
Published in Clinical cancer research (01.03.2017)
Published in Clinical cancer research (01.03.2017)
Get full text
Journal Article